SEATTLE — Sana Biotechnology, Inc. (Sana), focused on engineering cells as medicines for patients, announced today the funding of all tranches of its initial financing, raising over $700 million. 

With this financing, Sana’s shareholders include ARCH Venture Partners, Flagship Pioneering, Canada Pension Pl...

Founders: David Perry, Geoffrey von Maltzahn and Noubar Afeyan
CEO: David Perry
Launched: 2014
Headquarters: Boston
Funding: $850 million
Valuation: $3.5 billion
Key technologies: Artificial intelligence, machine learning
Industry: Agriculture, farming
Previous appearances on Disruptor 50 List: 2 (No. 1...

Cambridge-based Magenta Therapeutics announced today that it has entered a non-exclusive research and clinical collaboration agreement with Beam Therapeutics. The goal is to evaluate the potential use of MGTA-117, Magenta’s novel targeted antibody drug conjugate (ADC) for the conditioning of patients with...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of positive safety and bi...

• Multi-Target Collaboration Leverages Vividion's Screening Platform to Discover and Develop Highly Selective Small Molecules for E3 Ligases and Select Oncology and Immunology Targets

• Vividion Receives $135 Million Upfront Payment With Potential for Multi-Billion Dollar Future Payments

SAN DIEGO,...

• Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo

• Novel HbG-Makassar Program for Sickle Cell Disease Demonstrates Direct Correction Levels Greater than 80% with Corresponding HbS...

SAN DIEGO, April 30, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., today announced that preliminary results from an independent preclinical study showed that oncology product candidate zotatifin (eFT226) had in vitro antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The result...

Study Presented in Virtual Session at AACR Annual Meeting Provides Evidence of Potential for Zotatifin to Drug an Important Class of Oncogene Drivers

SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs)...

Vir's has two candidates that have proved highly potent in neutralising SARS-CoV-2 in live virus-cellular assays

GlaxoSmithKline PLC (LON:GSK) is to invest US$250mln into Nasdaq-listed Vir Biotechnology Inc (NASDAQ:VIR), with the two companies to work together on potential treatments for coronavirus.

It is...

San Francisco-based Vir Biotechnology indicated it has identified several human monoclonal antibody (mAb) candidates against SARS-CoV-2, the virus causing COVID-19. In the interest of saving time, the company’s lead development was transferred to WuXi Biologics and Biogen several weeks ago with human tria...